Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 19, 2007 Brian Lawler	The Best Drug Stock for 2007: Endo Pharmaceuticals This drug-maker just might be a great investment at the current price.
The Motley Fool April 30, 2007 Brian Lawler	Nothing Wrong With Endo Endo Pharmaceuticals releases first-quarter financial results. Investors, take note.
The Motley Fool February 26, 2007 Brian Lawler	Endo Brings in the Dough Why buy this pharmaceutical? Investors, let me count the ways.
The Motley Fool September 29, 2010 Brian Orelli	A Mini-Teva in the Making Generic growth by Endo Pharmaceuticals.
The Motley Fool January 10, 2007 Brian Lawler	Endo's Plan to Bring In the Dough Despite little movement in the value of their shares, 2006 was an eventful year for investors in drug developer Endo Pharmaceuticals.
The Motley Fool January 22, 2007 Brian Lawler	The Feds Eye Endo Endo Pharmaceuticals' sales practices for Lidoderm prompt government scrutiny. Investors don't seem too concerned.
The Motley Fool August 3, 2007 Brian Lawler	Endo Adjusting to Bigger Hopes The pharma announces its second-quarter financial results. As worries recede about near-term generic competition for lead drug Lidoderm, expectations for Endo have grown.
The Motley Fool April 1, 2008 Brian Lawler	The Endo a Patent? Endo sues to protect a lead drug from generic competition.
The Motley Fool November 6, 2007 Brian Lawler	The Two Sides of Endo It has been a mixed third quarter for Endo Pharmaceuticals. On the financial side of things the company performed well; on the research and development side, things are not as good.
BusinessWeek December 11, 2006 Michael Arndt	When A Winner Starts To Wane Endo is seeking to immunize itself from the slowing growth of its Lidoderm pain patch.
The Motley Fool February 25, 2008 Brian Lawler	The Yin and Yang of Endo Endo Pharmaceuticals' fiscal 2007 report offered positive year-end financial results and a little bit of balance-sheet sourness.
The Motley Fool April 30, 2007 Brian Orelli	No Pain for Endo's Investors Endo Pharmaceuticals had an impressive first quarter thanks to a new product and continued sales growth of its older brands. Investors, take note.
The Motley Fool January 30, 2008 Brian Lawler	The Endo a CEO Shares of Endo Pharmaceutical rise after its CEO, Peter Lankau, resigns.
The Motley Fool February 21, 2008 Brian Orelli	Watson Gets Less Generic Branded sales were up while generics fell for the year, which made Watson Pharmaceutical a more balanced company.
The Motley Fool August 1, 2007 Brian Lawler	Calling Out Endo Endo Pharmaceuticals gets taken to task by an activist investor. An investment group owning 5.6% of outstanding shares is concerned with how management plans to use $700 million available to them in cash and investments.
The Motley Fool March 20, 2007 Brian Lawler	A Slowdown at Endo The FDA delays a decision on expanding the label for one of Endo's drugs. Investors, take note.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
Chemistry World September 2, 2013 Emma Stoye	Endo Health to buy Boca Pharmacal for $225m US speciality healthcare company Endo Health Solutions has agreed to buy Boca Pharmacal for $225 million in a bid to expand its generics business.
The Motley Fool October 8, 2007 Brian Orelli	New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.
The Motley Fool October 3, 2007 Brian Lawler	FDA Says Nay to Endo Endo Pharmaceuticals announces that the FDA issued a "not approvable" letter in response to the company's attempt to expand the label for migraine treatment Frova.
The Motley Fool January 31, 2007 Brian Lawler	Mylan on the Generic Attack Two new drug approvals for the generic drugmaker come in the midst of a changing regulatory environment. Investors, take note.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
The Motley Fool April 7, 2011 Brandon Glenn	"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
Managed Care February 2008 Martin Sipkoff	FDA Approach to Generics May Be a Mixed Blessing A recently announced initiative is supposed to speed approval of generic drugs, but does it address some fundamental flaws in the approval process?
The Motley Fool June 1, 2005 Rich Duprey	Able Labs Disabled The generic drug maker recalls its entire inventory over quality concerns. Its stock price cratered 75% the day after the announcement and has since fallen another 30% since then.
The Motley Fool July 2, 2008 Brian Lawler	DURECT's Intriguing Little Orphan An exciting pain drug inches onward in development.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
The Motley Fool September 6, 2007 Brian Lawler	NeurogesX Feels No Pain Investors reward the drugmaker for positive study results.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.
The Motley Fool June 28, 2004 Jeff Hwang	Watson Pharmaceuticals Tumbles The generic drug business at Watson Pharmaceuticals is still going strong; it's the branded products that are causing trouble.
The Motley Fool June 22, 2006 Stephen D. Simpson	Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.
Chemistry World May 26, 2015 Phillip Broadwith	Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt.
The Motley Fool September 18, 2009 Brian Orelli	A 25% Stock Gain Will Ease Any Pain Glaxo and XenoPort's shingles drug gives the latter's shares a healthy boost.
Managed Care November 2005	Recently Introduced Generics Helped Pbm Control Its Costs The top five generic drugs released over the past three years reduced pharmacy spending by 4.8 percent largely due to the timing of the release of generic products to the market.
The Motley Fool April 30, 2008 Brian Lawler	The Start of a New Endo The drugmaker marks its first quarter under new management.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
The Motley Fool January 30, 2007 Brian Lawler	Par Passes the Generic Bar Par Pharmaceutical Companies gets approval to market another generic product, but the company still has to complete the restatement of its past financials. Investors, take note.
The Motley Fool January 31, 2008 Brian Lawler	A Zettlement for Zyprexa? Eli Lilly may be close to resolving a government lawsuit over improper marketing.
The Motley Fool December 30, 2008 Brian Orelli	2009's Generic Drugs: Who's at Risk The patent cliff is coming early for some drugmakers.
Managed Care May 2006 John Carroll	Effective Ways To Increase Usage of Generics Generics is one of the few areas where insurance plans can economize effectively. BlueCross & BlueShield of North Carolina is one of many insurers that are changing members' and prescribers' behavior.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
Managed Care September 2007 Martin Sipkoff	Patent Law Rulings Work in Favor of Generics Thanks to recent Supreme Court rulings, manufacturers of generic drugs are in a good position to continue expansion of their market share.
Pharmaceutical Executive October 1, 2005 Glass & Worrell	Whose Afraid of Authorized Generics Losing a patent challenge lets a generic competitor grab market share and slash branded profits. Sound scary? Ignoring authorized generics is worse.
Pharmaceutical Executive May 1, 2011 Stan Bernard	Competition 2.0: Brands vs. Generics Innovator and generics companies are colliding as they invade each other's turf.
The Motley Fool May 12, 2011 Brian Orelli	Teva's Mixed Bag Diversification sure helps.
Pharmaceutical Executive October 1, 2011	30 Years of Pharma: Perspective in Numbers, Part 3 Top 10 generics companies.
The Motley Fool December 28, 2007 Brian Lawler	Endo and Alexza Team Up Endo Pharmaceuticals and Alexza Pharmaceuticals announce a collaboration deal for an early-stage Alexza drug.
The Motley Fool May 21, 2009 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did.